YouTube Facebook LinkedIn Google+ Twitter Xinginstagram rss  

Short News & Analysis

June 25, 2009 | Entelos Retains Seven Hills Partners
Entelos has posted a copy of its proxy statement and proxy card, in connection with resolutions to be voted on at the Entelos Annual Stockholder Meeting taking place on June 23, 2009. It also announced that, “following receipt of unsolicited expressions of interest from certain third parties investigating the possibility of acquiring or entering into another strategic transaction with Entelos, the Company has retained Seven Hills Partners LLC as its financial advisor. Seven Hills is assisting the Company’s Board of Directors and senior management in evaluating various strategic alternatives which the Company hopes will enhance shareholder value, including various financing and capital raising alternatives.” Read release.

Ingenuity and Integromics Integration For Genomics Analysis
Integromics and Ingenuity Systems announced the integration of RealTime StatMiner and Integromics Biomarker Discovery (IBD) for Tibco Spotfire with Ingenuity Pathway Analysis (IPA).  The resulting platform provides a uniform solution for researchers to visualize and statistically assess genomics data, and then identify relevant biological processes and pathways.

“Our main objective is to provide our joint customers with relevant workflows that help them best understand their gene expression data,” said Tuan Nguyen, VP, Partner and Professional Services, Ingenuity Systems. “We felt it was important to provide a streamlined way for researchers to move from raw data analysis to understanding relevant biology.” Read release.

BioSeek and Merck Serono Extend 2008 Agreement
BioSeek signed a new, three-year collaboration agreement with Merck KGaA, acting for its division Merck Serono, extending and expanding the companies’ previous 2008 compound profiling agreement. Under the research plan, BioSeek will continue to use its proprietary BioMAP platform to evaluate Merck Serono small molecule compounds and proteins across multiple therapeutic areas in support of target differentiation, lead selection, and nomination of candidates for preclinical development at Merck Serono. Financial details were not disclosed. Read release.

This article first appeared in Bio-IT World’s Predictive Biomedicine newsletter. Click here for a free subscription.

Click here to login and leave a comment.  


Add Comment

Text Only 2000 character limit

Page 1 of 1

For reprints and/or copyright permission, please contact Angela Parsons, 781.972.5467.